48 completed. 48 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 48 | Completed 48 |
| Phase 2 | 4 | Completed 4 |
Follow Dyslipidemia: new trials by email Literature Review of Dyslipidemia trials Research Report on Dyslipidemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Bioequivalence Study of AJU-C715 and C715R in Healthy Adult Volunteers Test Drug, Reference Drug - Hypercholerolemia, Dyslipidemia | Phase 1 | Completed | AJU Pharm Co., Ltd. | 61 | 2026-08-06 | 2026-09-09 |
| To Evaluate the Safety and Pharmacokinetic Characteristics of AJU-C716 and C716R in Healthy Adults Test Drug, Reference Drug - Hypercholesterolemia, Dyslipidemia | Phase 1 | Completed | AJU Pharm Co., Ltd. | 41 | 2026-06-11 | 2026-07-10 |
| Study to Evaluate the Safety and the Pharmacokinetics of "UI111" and "UIC202006" Under Fed Conditions Administration of UI111, Administration of UIC202006 - Dyslipidemia | Phase 1 | Completed | Korea United Pharm. Inc. | 44 | 2025-02-13 | 2026-07-08 |
| ALN-APOC3 in Adult Participants With Dyslipidemia ALN-APOC3, Matching Placebo - Dyslipidemia | Phase 1 | Completed | Regeneron Pharmaceuticals | 32 | 2025-01-27 | 2026-03-16 |
| A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C. AZD0780, Ezetimibe, Rosuvastatin - Dyslipidemia | Phase 1 | Completed | AstraZeneca | 81 | 2024-12-20 | 2025-11-10 |
| A Phase I Clinical Study of a Single Subcutaneous Injection of HRS-5632 in Healthy Subjects HRS-5632, Placebo - Dyslipidemia | Phase 1 | Completed | Fujian Shengdi Pharmaceutical Co., Ltd. | 50 | 2024-12-02 | 2026-04-03 |
| Clinical Study to Evaluate Drug-drug Interaction and Safety After Co-administration of D352 and D794 in Healthy Adult Volunteers D352, D794 - Dyslipidemia | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 40 | 2024-11-27 | 2025-05-21 |
| A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of Rosuvastatin. AZD0780, Rosuvastatin - Dyslipidemia | Phase 1 | Completed | AstraZeneca | 16 | 2023-03-09 | 2025-04-27 |
| A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD0780 in Healthy Subjects AZD0780, Placebo, Rosuvastatin - Dyslipidemia | Phase 1 | Completed | AstraZeneca | 183 | 2022-05-18 | 2026-09-09 |
| A Study of AZD8233 in Participants With Dyslipidemia. Part A:Placebo, Part A:AZD8233, Part B:Placebo - Dyslipidemia | Phase 1 / Phase 2 | Completed | AstraZeneca | 87 | 2021-01-20 | 2024-12-24 |
| To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD8233 After Multiple Dose Administration in Subjects With Dyslipidemia AZD8233 subcutaneous injection, Placebo - Dyslipidemia | Phase 1 | Completed | AstraZeneca | 34 | 2019-11-21 | 2021-06-30 |
| A Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between YHR1705 and YHR1706 YHR1705, YHR1706, YHR1705+YHR1706 - Dyslipidemia, Type 2 Diabetes Mellitus | Phase 1 | Completed | Yuhan Corporation | 28 | 2017-08-07 | 2017-11-01 |
| Study to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519 CKD-519, Placebo - Dyslipidemia | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 18 | 2017-03-07 | 2017-07-07 |
| Study to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519 CKD-519, placebo - Dyslipidemia | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 24 | 2016-04-01 | 2017-07-13 |
| A Clinical Trial to Compare Safety and Pharmacokinetic Characteristics of CKD-337 Lipitor + Lipidil supra, CKD-337 - Dyslipidemia | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 48 | 2016-01-01 | 2016-07-07 |
| Study to Assess PK/PD Character, Safety/Tolerability of CKD-519 New Formulation in Healthy Male Subject. CKD-519 50mg 2Tabs., CKD-519 100mg 1Tab., CKD-519 100mg 1Cap. - Dyslipidemia | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 30 | 2015-10-01 | 2016-01-20 |
| ADME Study in Healthy Male Subjects With TA-8995 TA-8995 - Dyslipidemia | Phase 1 | Completed | Xention Ltd | 6 | 2015-06-01 | 2016-10-03 |
| Study to Investigate the Effect of Food on the Pharmacokinetics/Pharmacodynamics and Safety of CKD-519(CKD-519 FDI) CKD-519 200mg / Fasting, Standard Meal, High Fat Meal - Dyslipidemia | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 45 | 2015-06-01 | 2015-12-07 |
| Evaluation of Absorption, Metabolism, and Excretion and Estimation of the Absolute Bioavailability of K-312 K-312 100 mg, K-312 100 ug C14 IV - Dyslipidemia | Phase 1 | Completed | Kowa Research Institute, Inc. | 13 | 2014-08-01 | 2016-02-18 |
| Pharmacokinetics of Rosuvastatin and Atorvastatin in Pediatric Dyslipidemia Patients Rosuvastatin, Atorvastatin - Dyslipidemia | Phase 1 | Completed | Children's Mercy Hospital Kansas City | 28 | 2014-07-01 | 2019-01-31 |
Showing 20 of 48. Sign in to see all of them.
Dyslipidemias (48) · Hypercholesterolemia (8) · Cardiovascular Diseases (4) · Diabetes Mellitus, Type 2 (4) · Obesity (2) · Acute Coronary Syndrome (1) · Arachnodactyly (1) · Atherosclerosis (1) · Coronary Disease (1) · Diabetes Mellitus (1) · Hepatic Insufficiency (1) · Hyperlipidemias (1) · Hyperlipoproteinemia Type II (1) · Hypertension (1) · Ischemic Attack, Transient (1)
Lipid Metabolism Disorders (48) · Nutritional and Metabolic Diseases (48) · Metabolic Diseases (47) · Hyperlipidemias (8) · Endocrine System Diseases (5) · Glucose Metabolism Disorders (5) · Diabetes Mellitus (4) · Pathological Conditions, Signs and Symptoms (3) · Vascular Diseases (3) · Body Weight (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Heart Diseases (2) · Kidney Diseases (2)
CKD-519 (5) · Rosuvastatin Calcium (5) · Niacin (4) · Ezetimibe (3) · TA-8995 (3) · anacetrapib (3) · Atorvastatin (2) · Drug Evaluation (2) · Fenofibrate (2) · MK-0524 (2) · bococizumab (2) · 1-stearoyl-d35-2-docosahexaenoyl-sn-glycero-3-phosphocholine (1) · 2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid (1) · 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropanoic acid (1) · 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid (1)
Merck Sharp & Dohme LLC (8) · Chong Kun Dang Pharmaceutical (7) · AstraZeneca (5) · AJU Pharm Co., Ltd. (2) · Kowa Research Institute, Inc. (2) · Pfizer (2) · Tanabe Pharma Corporation (2) · Bristol-Myers Squibb (1) · C. T. Lamont Primary Care Research Centre (1) · Catabasis Pharmaceuticals (1) · Children's Mercy Hospital Kansas City (1) · Eli Lilly and Company (1) · Federico II University (1) · Fujian Shengdi Pharmaceutical Co., Ltd. (1) · Genfit (1)
United States (17) · South Korea (11) · United Kingdom (4) · Australia (1) · Brazil (1) · Canada (1) · China (1) · France (1) · Germany (1) · Japan (1) · Moldova (1)
Min-Su Park, Ph.D (2) · Allan Gordon, MD, PhD (1) · Ashley Brooks (1) · Clare E Liddy, MD, MSc (1) · David Han, MD (1) · Ji Young Kim, MD, PhD (1) · Jon B Wagner, DO (1) · Lukasz Biernat, M.D (1) · Michael H Davidson, MD,FACC (1) · Mingul Kim, MD (1)
PMID 24782116, PMID 28181260, PMID 37994400, PMID 38504437, PMID 20457158, PMID 21952084, PMID 22008366, PMID 22970753, PMID 26510577, PMID 27596224, PMID 28271017, PMID 28279967, PMID 28729361, PMID 28982667, PMID 29037448, PMID 42137960
K23HL091130 (1), R01HL108160 (1)